The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Dua, K; Wadhwa, R; Singhvi, G; Rapalli, V; Shukla, SD; Shastri, MD; Gupta, G; Satija, S; Mehta, M; Khurana, N; Awasthi, R; Maurya, PK; Thangavelu, L; Rajeshkumar, S; Tambuwala, MM; Collet, T; Hansbro, PM; Chellappan, DK

The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Wadhwa, R Singhvi, G Rapalli, V Shukla, SD Shastri, MD Gupta, G Satija, S Mehta, M Khurana, N Awasthi, R Maurya, PK Thangavelu, L Rajeshkumar, S Tambuwala, MM Collet, T Hansbro, PM

Chellappan, DK

Permalink

Publication Type:: Journal Article
Citation:: Drug Development Research, 2019, 80 (6), pp. 714 - 730
Issue Date:: 2019-09-01

Closed Access

	Filename	Description	Size
	Dua_et_al-2019-Drug_Development_Research.pdf	Published Version	2.65 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.contributor.author	Wadhwa, R	en_US
dc.contributor.author	Singhvi, G	en_US
dc.contributor.author	Rapalli, V	en_US
dc.contributor.author	Shukla, SD	en_US
dc.contributor.author	Shastri, MD	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Satija, S	en_US
dc.contributor.author	Mehta, M	en_US
dc.contributor.author	Khurana, N	en_US
dc.contributor.author	Awasthi, R	en_US
dc.contributor.author	Maurya, PK	en_US
dc.contributor.author	Thangavelu, L	en_US
dc.contributor.author	Rajeshkumar, S	en_US
dc.contributor.author	Tambuwala, MM	en_US
dc.contributor.author	Collet, T	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Chellappan, DK	en_US
dc.date.available	2019-05-21	en_US
dc.date.issued	2019-09-01	en_US
dc.identifier.citation	Drug Development Research, 2019, 80 (6), pp. 714 - 730	en_US
dc.identifier.issn	0272-4391	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136344
dc.description.abstract	© 2019 Wiley Periodicals, Inc. Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.	en_US
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation.ispartof	Drug Development Research	en_US
dc.relation.isbasedon	10.1002/ddr.21571	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Drug Carriers	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	RNA, Small Interfering	en_US
dc.subject.mesh	Respiratory Tract Diseases	en_US
dc.title	The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress	en_US
dc.type	Journal Article
utslib.citation.volume	6	en_US
utslib.citation.volume	80	en_US
utslib.for	0604 Genetics	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Students
utslib.copyright.status	closed_access
pubs.issue	6	en_US
pubs.publication-status	Published	en_US
pubs.volume	80	en_US

Abstract:

© 2019 Wiley Periodicals, Inc. Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136344